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Abstract 
Marfan syndrome (MFS) is a rare genetic disease characterized by a matrix metalloproteases (MMPs) 
dysregulation that leads to extracellular matrix degradation. Consequently, MFS patients are prone to 
develop progressive thoracic aortic enlargement and detrimental aneurysm. Since MMPs are activated by 
the extracellular MMP inducer (EMMPRIN) protein, we determined whether its plasmatic soluble form 
(sEMMPRIN) may be considered a marker of thoracic aortic ectasia (AE).  
Methods: We compared plasma sEMMPRIN levels of 42 adult Caucasian MFS patients not previously 
subjected to aortic surgery with those of matched healthy controls (HC) by ELISA. In the MFS cohort we 
prospectively evaluated the relationship between plasma sEMMPRIN levels and the main MFS-related 
manifestations.  
Results: MFS patients had lower plasma sEMMPRIN levels (mean±SD: 2071±637 pg/ml) than HC 
(2441±642 pg/ml, p=0.009). Amongst all considered MFS-related clinical features, we found that only 
aortic root dilatation associated with circulating sEMMPRIN levels. Specifically, plasma sEMMPRIN levels 
negatively correlated with aortic Z-score (r=-0.431, p=0.004), and were significantly lower in patients 
with AE (Z-score≥2, 1788±510 pg/ml) compared to those without AE (Z-score<2, 2355±634 pg/ml; 
p=0.003). ROC curve analysis revealed that plasma sEMMPRIN levels discriminated patients with AE 
(AUC [95%CI]: 0.763 [0.610–0.916], p=0.003) with 85.7% sensitivity, 76.2% specificity, and 81% accuracy. 
We defined plasma sEMMPRIN levels ≤2246 pg/ml as the best threshold discriminating the presence of 
AE in MFS patients with an odds ratio [95%CI] of 19.2 [3.947-93.389] (p<0.001).  
Conclusions: MFS patients are characterized by lower sEMMPRIN levels than HC. Notably, plasma 
sEMMPRIN levels are strongly associated with thoracic AE. 
Key words: Marfan syndrome; aortic ectasia; EMMPRIN; thoracic aortic aneurysm; Z-score. 
Introduction 
Marfan syndrome (MFS) is a connective tissue 
disease with an autosomal dominant inheritance and 
an estimated incidence of 1:5000 individuals [1]. This 
condition is caused by mutations in the FBN1 gene 
encoding for fibrillin-1, an extracellular matrix (ECM) 
component that, by forming complex structures called 
microfibrils, provides elasticity and structural support 
to tissues [2]. As consequence, this genetic defect leads 
to pleiotropic manifestations in various body regions 
such as the skeletal, ocular and cardiovascular 
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systems [3]. In particular, progressive thoracic aortic 
aneurysm (TAA) formation and dissection are the 
leading causes of death in MFS patients [4,5]. For this 
reason, the efforts of the scientific community are 
directed towards finding novel therapeutic 
approaches, as well as early diagnostic tools, to limit 
MFS aortic dilatation [6].  
To date, although the pathways driving aortic 
disease pathogenesis in MFS have been deeply 
investigated, a comprehensive molecular mechanism 
is still missing [7]. Macroscopically, the development 
of aortic disease in MFS can be explained by simple 
tissue alterations, due to defective assembly of elastin 
into elastic fibres. Recent investigations have, 
however, shown a more complex scenario, with the 
involvement of transforming growth factor-β (TGF-β) 
and angiotensin II-dependent pathways [8,9], as well 
as ECM-dependent alterations [10-12]. The latter 
involves a group of enzymes called matrix 
metalloproteases (MMPs) and their inhibitors (tissue 
inhibitor of metalloproteases, TIMP) that regulate 
ECM component turnover. In MFS Segura et al. 
established a vicious cycle according to which defects 
in fibrillin-1 per se lead to the up-regulation of MMP 
synthesis and the accumulation of abnormally 
aggregated elastin which, in turn, is highly 
susceptible to be degraded by MMPs [13]. The crucial 
role of MMPs in MFS was confirmed by treating a 
mouse model of MFS (Fbn1C1039G/+) with doxycycline 
which prevents MMP production and secretion, 
determining a decrease in elastic fibre degeneration, 
vasomotor function normalization, and inhibition of 
TGF-β activation [10,14]. 
The extracellular MMP inducer (EMMPRIN) is a 
receptor capable of stimulating the production of 
various MMPs, such as MMP-1, MMP-2, MMP-3, 
MMP-9, and MMP-11 [15-17]. EMMPRIN is a cell 
surface transmembrane glycoprotein that, mainly 
through interacting with cyclophilin A, is involved in 
several cellular processes including the induction of 
MMPs, migration, inflammation, and transport of 
nutrients [18]. These functions provide the molecular 
basis for the role of EMMPRIN in the pathogenesis of 
several diseases such as cancer, infectious diseases 
(e.g. malaria), rheumatoid arthritis, myocardial 
infarction, multiple sclerosis, and renal fibrosis 
[17,19-24]. It is important to note that EMMPRIN is 
present in vascular smooth muscle cells of human 
aneurysmal aortas [25] and that its expression is 
induced by angiotensin II and TGF-β administration 
in vitro [25,26]. 
Emerging evidences indicate the presence of 
further forms of EMMPRIN in addition to the 
transmembrane form. Indeed, EMMPRIN has been 
detected in human serum and plasma where it is 
present as a soluble form (sEMMPRIN) derived from 
the proteolytic cleavage of the transmembrane 
receptor or from cell secretion via microvesicle 
shedding [27,28]. Currently, it is well known that 
sEMMPRIN acts in a paracrine fashion to stimulate 
the production of MMPs [29,30], thereby contributing 
to numerous diseases. For instance, increased 
sEMMPRIN levels are present in blood of patients 
with acute myocardial infarction and stable coronary 
artery disease, cancer, multiple sclerosis, and systemic 
sclerosis [31-36].  
Considering the importance of MMPs in MFS 
pathogenesis, we designed this study to investigate 
whether sEMMPRIN levels are altered in the plasma 
of MFS patients presenting different clinical profile, 
thus offering a rationale for being considered a 
potential diagnostic tool and/or therapeutic target in 
MFS-associated phenotypes. To this aim, we firstly 
examined plasma sEMMPRIN levels in MFS patients 
and compared the results with healthy subjects. Then, 
we prospectively evaluated the relationship between 
plasma sEMMPRIN levels and several clinical 
markers of MFS extent and TAA progression. 
Methods 
MFS patients 
Adult Caucasian subjects (≥18 years) affected by 
MFS and afferent to the Rare Disease Center-Marfan 
Clinic (ASST Fatebenefratelli-Sacco, Milan, Italy), in 
which the presence of FBN1 mutation was confirmed 
and without previous aortic surgery, have been 
screened for inclusion in this study (Figure S1). MFS 
was diagnosed according to the revised Ghent 
nosology [37]. Criteria determining the exclusion of 
MFS patients from the enrolment in this study were 
the presence of acute or chronic inflammatory state, 
precocious menopause, cardiac rheumatic disease, 
asthmatic disease, malignant cancer, systemic or 
multiple sclerosis, chronic hepatic disease and/or 
chronic renal failure (creatinine > 1.5 mg/dl), as well 
as the manifestation of acute myocardial infarction 
and/or coronary artery disease.  
Patient characteristics (e.g. sex, age, height, 
weight) and clinical data concerning MFS (e.g. 
systemic score, familial history of the disease, 
presence of skeletal manifestation, ectopia lentis, 
dural ectasia, mitral valve prolapse, aortic valve 
regurgitation, and aortic root diameter at the sinus of 
Valsalva) were collected and included in our patient 
registry. Treatments with β-blockers (BB) and/or 
angiotensin II receptor blockers (ARB) were also 
recorded and considered for the analyses. 
Additional/alternative hypotensive drug 
administration (e.g. calcium channel blockers and/or 
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angiotensin converting enzyme inhibitors) were also 
recorded. Importantly, we categorized for sex the 
cohort of 45 patients eligible for the enrolment in this 
study. On the basis of the Z-scores of the two 
subgroups, we excluded 3 outlier patients in order to 
avoid a gender-related Z-score unbalance (Figure S1). 
The clinical profile of the eligible vs. enrolled patients 
has been compared and no statistical difference 
between the two groups has been found (Table S1). 
The final study population has therefore included 42 
patients of which 29 had at least one MFS affected 
family member known to carry a mutation in FBN1 
and, thus, were screened only for the FBN1 mutation. 
The remaining 13 probands without known familiar 
MFS cases were evaluated according to phenotype by 
Next Generation Sequencing (NGS) for both FBN1 
and other genes commonly associated with Heritable 
Thoracic Aortic Disorders  including FBN1, TGFBR1, 
TGFBR2, MYH11, SMAD3, ACTA2, COL1A1, COL1A2, 
COL3A1, COL5A1, COL5A2 [38]. 
This study was authorized by the Ethics 
Committee of the ASST Fatebenefratelli-Sacco (Prot. 
N° 39138/2016). 
Aortic root echocardiographic evaluation 
Patient’s aortic root dilatation was evaluated by 
measuring the vessel diameter at the Valsalva sinus 
level by using the -EnVisor CHD- Ultrasound System 
(Philips). The two-dimensional echocardiographic 
measurements were determined during diastole by 
the leading edge-to-leading edge technique, as 
previously described in the literature [39]. At least 
three replications were performed in blind by the 
same operator to determine the mean value of the 
aortic root diameter. The relative intra-observer 
coefficient of variability between triplicates has been 
calculated to be 0.84%. Aortic valve regurgitation and 
mitral valve prolapse were also evaluated by 
echocardiography.  
Patients’ parameter calculations 
Body surface area (BSA) was calculated with the 
Du Bois and Du Bois’ formula [40]:  
Height (cm)0.725 * Weight (kg)0.425 * 0.007184 
As an index to evaluate aortic dilatation at the 
Valsalva sinus level, the Z-score was calculated by 
Devereux’s formula based on the normalization of the 
aortic diameter measurement for patients’ height, 
since this index was recently reported as the most 
appropriate method for aortic root assessment in MFS 
diagnostic evaluation [41]. The Z-score was calculated 
considering sex covariate value as 1 for males and 2 
for females by using the following the equation:  
(Sinus of Valsava diameter(cm) – [1.519 + (age * 0.010) + 
(height * 0.010) – (gender * 0.247)]) / 0.215 
Aortic ectasia (AE) was diagnosed when Z-score 
was ≥ 2.0 [37]. 
MFS patients’ sample collection 
For each patient enrolled in the study, 8 ml of 
peripheral whole blood was collected using EDTA 
Vacutainer tubes (BD). Plasma was obtained after 
centrifuging the whole blood for 10 minutes at 2500 g, 
at 4°C. 
Healthy controls 
Plasma samples collected on EDTA from healthy 
controls (HC) were purchased by NeoBiotech 
(Nanterre, France). Then HC were matched for sex 
and age with MFS counterparts. Age matching was 
computer-generated selecting minimal age difference 
between HC and MFS. Moreover, to exclude a 
possible bias, a statistical analysis to assess possible 
differences between HC and MFS patient age was also 
performed. The age of HC (median [IQR]: 35 [29-40]) 
did not result statistically different from that of MFS 
patients (35 [29-48]; p=0.336). 
sEMMPRIN evaluation 
Plasma sEMMPRIN levels were quantified by a 
commercial enzyme-linked immunosorbent assay 
(Human EMMPRIN/CD147 Quantikine ELISA, R&D 
Systems) following the manufacturer's instructions. 
The sEMMPRIN concentration in each sample was 
determined by interpolation of a linear standard 
curve obtained by plotting the logarithm of human 
sEMMPRIN concentrations versus the logarithm of the 
absorbance. Each sample was tested in triplicate. 
Statistical analyses 
Data with Gaussian distribution were expressed 
as mean ± standard deviation (SD), while data with 
non-parametric distribution were expressed as 
median and IQR. The Fisher’s exact test was 
performed to compare the distribution of categorical 
variables. To assess the normal distribution of each 
covariate the D'Agostino-Pearson omnibus K2 and the 
Shapiro-Wilk normality tests were performed, as 
appropriate (> and ≤20 samples, respectively). 
T-student and Mann Whitney U tests were performed 
to compare plasma sEMMPRIN levels between 
subgroups of patients, as appropriate. One-way 
ANOVA was performed to evaluate differences 
among means, and post-hoc multiple comparisons 
were analysed using Bonferroni’s test. Two-way 
ANOVA was performed to evaluate the influence of 
two independent categorical variables on one 
dependent variable and their possible interaction. 
Pearson and Spearman’s rank correlation tests were 
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used to assess the statistical dependence of two 
parametric or non-parametric variables, respectively. 
Receiver Operating Characteristic (ROC) curve 
analysis was performed to quantify how accurately 
the sEMMPRIN levels could discriminate patients 
who developed AE. Specifically, the criterion 
corresponding with the highest Youden’s index was 
used as a cut-off to categorize the sEMMPRIN levels 
with the highest sum of sensitivity and specificity [42]. 
Univariable logistic regression analysis was 
performed to assess the OR [95%CI] of the association 
between sEMMPRIN levels and AE development 
after sEMMPRIN level dichotomization performed on 
the basis of the cut-off value obtained with the ROC 
curve analysis. The evaluation of age and sex as 
possible confounding factors in the association 
between sEMMPRIN levels and AE development was 
assessed including these covariates as independent 
variables in a multivariable logistic regression model. 
Statistical significance was set at p value <0.05. All the 
analyses were performed with GraphPad Prism® 
software (version 5.0) and with MedCalc. 
Results 
Patients clinical characteristics 
Forty two MFS adult patients fulfilled the 
inclusion criteria and were enrolled for this study. 
Patients’ clinical profiles are summarized in Table 1, 
while FBN1 mutations found in the whole cohort are 
reported in Table S2. All patients were Caucasians 
and had not been subjected to any previous aortic 
surgery. The cohort included 16 males and 26 females. 
Patients’ ages at enrolment ranged from 18 to 61 
years, with a median [IQR] of 35 [29-48] (Table 1). 
Patients’ heights ranged from 162 to 198 cm with a 
mean±SD of 178±10 cm, patients’ weights ranged 
between 42 and 114 kg with a mean of 71.6±16.4 kg, 
and BSA of the cohort was 1.88±0.22 m2 (Table 1). 
Disease phenotype in our MFS cohort was rather 
variable: patients’ systemic scores ranged from 2 to 16 
with a mean of 9.3±3.3. Concerning familial history of 
the disease, 29 patients had at least one first- and/or 
second-degree relative with a diagnosis of MFS (69%). 
Of note, 6 participants had a first-degree (n=3) or a 
second-degree (n=3) relative included in the cohort 
(Table S2). All patients developed skeletal 
manifestations, 16 out of 42 developed ectopia lentis 
(38.1%) and 24 out of 33 dural ectasia (72.7%), as 
reported in Table 1. Cardiovascular manifestations in 
these patients were prevalent (95.2%), affecting 
patients at different degrees. Mitral valve prolapse 
was recorded in 33 out of 40 patients (82.5%) and 
aortic valve regurgitation in 6 out of 42 patients 
(14.3%). Patients’ Z-scores ranged from -2.26 to +5.48 
with a mean of 1.91±1.79 (Table 1). Interestingly, 50% 
of patients showed Z-score ≥ 2 at enrolment and, thus, 
were defined as presenting with AE. As for inclusion 
criteria, aortic size was similar in males (Z-score: 
1.83±1.60) and females (1.95±1.92, p=0.840). 
 
Table 1: MFS outpatient clinical setting. Data are expressed 
as percentage, median [IQR], or mean±SD, as appropriate. 
*Evaluated only in 33 patients, †evaluated only in 40 patients, 
‡calculated with the Devereux’s formula with correction for 
height. BSA: body surface area, BB: β-blockers, ARB: angiotensin 
receptor blocker.  
Patients’ profile n  
   
 Male 16 38.1% 
 Female 26 61.9% 
 Age (yr) 42 35 [29-48] 
 Height (cm) 42 178±10 
 Weight (kg) 42 71.6±16.4 
 BSA (m2) 42 1.88±0.22 
Systemic phenotype   
 Systemic score 42 9.3±3.3 
 MFS familial history 29 69% 
 Skeletal manifestation 42 100% 
 Ectopia lentis  16 38.1% 
 Dural ectasia*  24* 72.7% 
 Mitral valve prolapse† 33† 82.5% 
Aortic phenotype   
 Aortic valve regurgitation  6 14.3% 
 Z-score‡ 42 1.91±1.79 
 Aortic ectasia (Z-score≥2) 21 50% 
Antihypertensive pharmacological treatment 
 BB 1 2.4% 
 ARB 12 28.6% 
 BB+ARB 16 38.1% 
 None 13 30.9% 
 
Concerning hypotensive drug administration at 
the time of enrolment, 1 out of 42 patients was treated 
with BB only, 12 were treated with ARB only, 16 with 
both BB and ARB, while 13 were not subjected to any 
pharmacological treatment following physician 
prescription or patients’ personal choice (Table 1). It is 
important to note that none of these patients were 
treated with calcium channel blockers and/or 
angiotensin converting enzyme inhibitors.  
Differences in plasma sEMMPRIN levels 
between MFS patients and healthy controls 
Circulating sEMMPRIN levels in 42 MFS 
patients and 42 matched HC have been measured. 
Plasma sEMMPRIN levels were significantly lower in 
MFS patients (2071±637 pg/ml) than in HC (2441±642, 
p=0.009; Figure 1A). To exclude a possible bias 
determined by familiar clustering in this cohort, a 
sensitivity analysis on the 36 unrelated probands was 
performed. Interestingly, plasma sEMMPRIN levels 
in these MFS patients remained statistically lower in 
respect to matched HC (2099±648 vs. 2445±608, 
p=0.022).  
To exclude possible confounding effects of age or 
pharmacological treatment in our MFS cohort, we 
firstly correlated sEMMPRIN plasmatic concentration 
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with age and then we categorized patients for their 
pharmacological treatment. As shown in Figure 1B 
and C, neither patients’ age (Spearman r=-0.101, 
p=0.524) nor the different antihypertensive treatment 
(ANOVA p=0.813) influenced plasma sEMMPRIN 
levels. 
We then checked whether sex might impact 
circulating sEMMPRIN. Interestingly, we found that 
plasma sEMMPRIN levels were significantly higher in 
males than in females both in HC (p=0.031, Figure 2A) 
and MFS patients (p=0.022, Figure 2B). Nevertheless, 
the breakdown of individual changes between 
matched HC and MFS patients did not reveal 
significant sex-related differences (males vs. females, 
336±612 vs. 446±957 pg/ml; p=0.692, Figure 2C). 
To further assess the influence of being affected 
by MFS and of sex on circulating sEMMPRIN levels 
we performed a two-way ANOVA that confirmed the 
significant influence of the MFS disease (p=0.009) and 
of sex (p=0.003) on sEMMPRIN level expression, but 
failed to prove an interaction between the two 
variables (p=0.784). 
sEMMPRIN levels and MFS systemic features 
We then investigated whether plasma 
sEMMPRIN levels correlate with patients’ clinical 
phenotype. In particular, we focused our attention on 
the most important MFS-related systemic and aortic 
manifestations. As for the systemic manifestations, 
circulating sEMMPRIN levels did not correlate with 
systemic score (Pearson r=0.157, p=0.319; Figure 3A). 
Moreover, plasma sEMMPRIN levels were similar 
between patients with and without a MFS familial 
history (2073±680 vs. 2067±554 pg/ml, p=0.976; Figure 
S2). Similarly, sEMMPRIN levels did not differ in 
patients presenting or not ectopia lentis (2030±774 vs. 
2097±552 pg/ml, p=0.746; Figure 3B), dural ectasia 
(2020±624 vs. 2327±712 pg/ml, p=0.234; Figure 3C), 
and mitral valve prolapse (2088±656 vs. 2093±584 
pg/ml, p=0.985; Figure 3D). 
Negative correlation between plasma 
sEMMPRIN levels and MFS patients’ aortic 
features  
As for MFS aortic phenotype, plasma 
sEMMPRIN levels were similar in patients who 
developed or not aortic valve regurgitation (2164±689 
vs. 2056±637 pg/ml, p=0.706; Figure 4A). 
We next found that patients’ Z-scores 
significantly negatively correlated with plasma 
sEMMPRIN levels (Pearson r=-0.431, p=0.004), as 
shown in Figure 4B. Specifically, lower levels of 
plasma sEMMPRIN were found in patients 
characterized by higher Z-scores, thus presenting a 
more severe aortic dilatation. Interestingly, after 
performing a categorization for sex, the correlation 
 
Figure 1: Plasma sEMMPRIN levels in healthy control and MFS patient cohorts. Differences in plasma sEMMPRIN levels of MFS patient and healthy control cohorts 
considered overall (A). Correlation between plasma sEMMPRIN levels and age in MFS patients (B). Plasma sEMMPRIN levels in patients treated with different hypotensive drugs 
(C). ARB: angiotensin II receptor blocker, BB: β-blockers. **p<0.01. 
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between Z-score and plasma sEMMPRIN levels was 
confirmed both in males (Pearson r=-0.551, p=0.027) 
and in females (Pearson r=-0.408, p=0.039; Figure S3). 
Then, we adopted the Z-scores to categorize patients 
showing AE, defined as patients with a Z-score level ≥ 
2, and those without AE (Z-score level < 2). 
Consistently with previous findings, patients with AE 
showed significantly lower plasma sEMMPRIN levels 
(1788±510 pg/ml) versus those without AE (2355±634 
pg/ml, p=0.003; Figure 4C).  
 
 
Figure 2: Circulating sEMMPRIN levels in male and female HC and MFS patients. Differences in plasma sEMMPRIN levels in HC (A) and MFS patients (B) categorised 
for sex. Delta sEMMPRIN levels between matched HC and MFS patients categorized for sex (C). HC: healthy controls; MFS: Marfan syndrome. *p<0.05. 
 
Figure 3: Plasma sEMMPRIN levels in MFS patients characterized by different systemic phenotype. Correlation between plasma sEMMPRIN levels and patients’ 
systemic score (A). Differences in plasma sEMMPRIN levels in patients developing or not ectopia lentis (B), dural ectasia (C) or mitral valve prolapse (D). w/o: without, w: with. 
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Figure 4: Plasma sEMMPRIN levels in MFS patients characterized by different aortic phenotype. Difference in plasma sEMMPRIN levels in patients with or without 
aortic valve regurgitation (A). Correlation between plasma sEMMPRIN levels and patients’ Z-score (B) and difference in plasma sEMMPRIN levels in patients with or without 
aortic ectasia (C). w/o: without, w: with. **p<0.01. 
 
To further investigate the sEMMPRIN value as 
discriminator, we performed a comparison with other 
circulating molecules previously found to be related 
to aortic dilatation (e.g. MMP-2, MMP-9, TIMP-1, and 
TGF-β1) [43-46] by correlating their levels detected in 
patients’ circulation with the Z-scores. Interestingly, 
none of the evaluated plasma biomarkers in our MFS 
cohort significantly correlated with patients’ Z-scores 
(Figure S4). Moreover, to evaluate whether 
sEMMPRIN yielded independent information in 
respect to other proposed biomarkers, we correlated 
plasma sEMMPRIN levels with MMP-2, MMP-9, 
TIMP-1, and TGF-β1 levels. Interestingly, we did not 
find any significant correlation between plasma 
sEMMPRIN and the evaluated molecules (Figure S5). 
Plasma sEMMPRIN levels discriminate the 
presence of aortic ectasia 
We subsequently performed a ROC curve 
analysis to assess whether plasma sEMMPRIN levels 
could reveal the presence of AE in MFS patients. 
Interestingly, the area under the curve (AUC) 
obtained by the ROC analysis was as high as 0.763 
(95% CI: 0.610–0.916), denoting the ability of plasma 
sEMMPRIN levels to discriminate patients with or 
without AE (p=0.003, Figure 5A). We also calculated 
that the optimal cut-off value for plasma sEMMPRIN 
was 2246 pg/ml. This threshold, obtained considering 
the highest sum of sensitivity and specificity, 
provided 85.7% sensitivity (correctly classifying 18 
out of the 21 patients with AE) and 76.2% specificity 
(correctly classifying 16 out of the 21 patients without 
AE). Furthermore and notably, such a cut-off for 
plasma sEMMPRIN level showed a positive 
predictive value of 78.3%, a negative predictive value 
of 84.2% and an accuracy of 81.0% in predicting AE in 
MFS patients. Then, we estimated the Odd ratio (OR) 
by a logistic regression model to evaluate the 
association between circulating sEMMPRIN levels 
and the development of AE. Consistently with our 
previous results, plasma sEMMPRIN levels ≤2246 
pg/ml were associated with a considerably higher 
frequency of AE development (OR [95%CI]: 19.2 
[3.947-93.389], p<0.001; Figure 5B). Moreover, to 
exclude sex and age as possible confounding factors, 
we performed a multivariable logistic regression 
analysis, confirming the association between plasma 
sEMMPRIN levels and the development of AE 
independently from these two variables (adjusted OR 
[95%CI]: 36.05 [3.815-340.621], p=0.002; Figure 5C). 
Finally, we performed a sensitivity analysis on 
the 36 unrelated probands to exclude a possible bias 
determined by familiar clustering. Among these 
patients the 17 with AE had plasma sEMMPRIN 
levels lower than the 19 patients without AE 
(1805±535 vs. 2362±637 pg/ml, p=0.008). Furthermore, 
also in this subgroup of patients, plasma sEMMPRIN 
levels resulted significantly associated with the 
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presence of AE both by ROC curve analysis 
(AUC=0.757 [95%CI: 0.590-0.924], p=0.009) and by OR 
(17.5 [3.311-92.477], p<0.001).  
Discussion 
ECM remodeling is crucial in determining 
MFS-TAA development and dissection. In this 
context, several determinants of ECM remodeling 
have been investigated as potential circulating 
biomarkers [43-48]. Circulating levels of fibrillin-1 
fragments have been found to be associated with the 
development of TAA in MFS patients [49]. Moreover, 
TGF-β levels were positively correlated with aortic 
root dimensions and aortic root growth [44], even if 
previous evidence failed to correlate TGF-β levels 
with Z-score or aortic diameter at the Valsalva sinus 
level [50,51]. Finally, homocysteine plasma levels, as 
well as the prevalence of homozygous genotypes of 
folic acid metabolism enzymes, correlated with severe 
cardiovascular manifestations and aortic dissection in 
MFS patients [52,53]. Nevertheless, at present an 
established clinical-grade circulating biomarker is still 
lacking.  
Of interest, MMPs are key players in 
exacerbating ECM degradation triggered by 
functional fibrillin-1 deficiency [13]. Notably, MMP-2 
and MMP-9 were up-regulated in TAA tissue and 
aortic valves of MFS patients [13]. A more 
recent study showed higher levels of 
MMP-12, MMP-14, and TIMP-2 in 
MFS-TAA when compared to other TAA, 
indicating that TAA in MFS possess a very 
distinctive tissue expression profile of 
MMPs and TIMPs, suggestive of a specific 
modulator [43].  
Several MMPs are regulated by 
EMMPRIN, a transmembrane glycoprotein 
receptor also found in a soluble plasmatic 
form [28]. While the receptor directly acts 
as a MMP inducer [15-17], the soluble 
protein appears to work in a paracrine 
fashion and it was recently proposed as a 
circulating biomarker in several diseases 
[31-36]. Although it is reported that 
sEMMPRIN levels are elevated in the blood 
of patients with acute myocardial 
infarction, coronary artery disease, cancer, 
and multiple and systemic sclerosis [31-36], 
in our study we detected lower circulating 
sEMMPRIN levels in MFS patients 
compared to HC. Moreover, in our MFS 
cohort we found that sEMMPRIN levels 
negatively correlated with patients’ aortic 
dilatation extent at the Valsalva sinus level. 
It can be speculated that these findings may 
reflect an elevated presence of the full-length and 
active form of EMMPRIN in the cell membrane. 
Indeed, it has been recently reported that active 
transmembrane EMMPRIN is abundant in the 
vascular smooth muscle cells of TAA tissue [25]. Thus, 
it is possible that, in the MFS pathological context, the 
cleavage of the full-length form of EMMPRIN, as well 
as its secretion from cells through vesicles, are 
blocked which leads to higher EMMPRIN expression 
in the cell membrane, consequently inducting MMP 
expression and activation in the tissue. Future studies 
are, however, warranted to define the precise 
mechanisms regulating sEMMPRIN in MFS-TAA.  
In this work, we also found that sEMMPRIN 
levels are influenced neither by age nor by treatment 
with the ARB Losartan and/or the BB Atenolol. 
Together these results allow us to exclude age and 
antihypertensive treatment as confounding factors for 
the subsequent analyses. Interestingly, we found that 
circulating sEMMPRIN levels were lower in females 
than in males both in HC and MFS patients. 
Mechanistically, several studies indicate MMPs and 
other metalloproteinases as candidates responsible for 
sEMMPRIN cleavage and/or secretion in different 
pathological contexts [28]. Notably, it has been 
reported that MMP expression is sex-related both in 
pathological and healthy conditions [54-57]. Such a 
 
Figure 5: Performance of the plasma sEMMPRIN level as discriminator for AE. ROC curve 
analysis of plasma sEMMPRIN levels found in MFS patients who developed (n=21) or not (n=21) aortic 
ectasia (A). Logistic regression analyses performed to assess the association between plasma sEMMPRIN 
levels and AE development without (B) and with (C) the inclusion of sex and age covariates in the model. 
AUC: area under the curve, CI: confidence intervals, OR: Odd ratio, F: female, M: male. 
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sex-dependent association between MMP expression 
and sEMMPRIN levels needs further investigations in 
the MFS-TAA setting. Nevertheless, we believe our 
data clearly show that sex-related differences in 
sEMMPRIN levels are independent from the presence 
of the disease. Moreover, we can also exclude that 
these differences in sEMMPRIN levels are due to 
variability in thoracic aortic phenotype severity, since 
male and female patients have been selected at 
enrolment with a similar Z-score. 
We evaluated whether the circulating 
sEMMPRIN levels could predict some MFS 
pathological features. Interestingly, beside the 
pathological systemic and cardiovascular features 
considered, plasma sEMMPRIN levels were strongly 
and selectively associated with the severity of aortic 
dilatation. In fact, our results indicate that 
sEMMPRIN levels negatively correlated with the 
extent of the aortic dilatation according to the Z-score. 
Specifically, patients with higher Z-scores –and, thus, 
more pronounced aortic enlargement– had lower 
circulating sEMMPRIN levels. 
Furthermore, we also uncovered that patients 
showing AE (Z-score ≥2) have lower sEMMPRIN 
levels than those with a milder aortic enlargement 
(Z-score <2) and, even more important, circulating 
sEMMPRIN levels ≤2246 pg/ml can discriminate 
patients with AE with a sensitivity as high as 85.7%. 
To the best of our knowledge, this is the first study to 
introduce a potential role for circulating sEMMPRIN 
in predicting AE amongst MFS patients which opens 
new perspectives in this pathological context for 
mechanistic studies on the involvement of the 
underlying pathway in aortic tissue remodeling. 
Importantly, the high sensitivity reached with this test 
along with the 81.0% accuracy indicate that 
sEMMPRIN levels may have implications in the 
management of MFS patients, since the identification 
of patients at higher risk of AE onset is of primary 
importance to prevent TAA development and 
dissection, the leading cause of death in MFS [4]. To 
date, the most widespread tools for measuring patient 
aortic diameter are imaging techniques such as 
transthoracic echocardiography, computed 
tomography and magnetic resonance imaging which 
allow an effective monitoring of aortic diameter 
progression [58]. The added value, on top of current 
clinical practice, of new biochemical information in 
this context may help to further discriminate subset of 
patients at higher risk [59]. Although still preliminary, 
our data suggest sEMMPRIN as a novel and 
promising circulating molecule among others already 
introduced in the literature as related to AE. 
Study limitations and future perspectives 
Our current findings are not conclusive to define 
sEMMPRIN levels as biomarker for aortic ectasia in 
MFS patients, due to the relatively small sample size 
of this proof-of-concept study. Nevertheless, it is 
important to highlight that the identification of 
sEMMPRIN as a novel potential specific discriminator 
for thoracic AE in MFS patients may represent the 
basis for future larger multicentric confirmative 
longitudinal studies.  
Conclusions 
In conclusion, our results suggest that plasma 
sEMMPRIN could be a useful and valuable adjuvant 
tool complementing imaging techniques for detecting 
AE development in MFS patients. Moreover, beside 
its potential diagnostic value, our data provide a 
rationale for further studying EMMPRIN 
glycoprotein in MFS pathological context with the aim 
to mechanistically investigate associated downstream 
pathways related to ECM remodeling, as well as to 
identify possible therapeutic targets to prevent or 
limit TAA progression. 
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